# DoD Prostate Cancer, Clinical Consortium Award

Source: https://welltoldgrants.com/grants/w81xwh-21-pcrp-cca-dod-prostate-cancer-clinical-consortium-award/  
Official notice: https://www.grants.gov/search-results-detail/332743

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 11 awards worth $30.7 million in total. Applications closed on September 23, 2021.

| Field | Value |
|---|---|
| Opportunity number | W81XWH-21-PCRP-CCA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | September 23, 2021 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 11 |
| Total funding | $30.7 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The Clinical Consortium Award mechanism provides the support to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute phase 2 or phase 2-linked phase 1 (phase 1/2) prostate cancer clinical trials. These trials will include investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of prostate cancer as pertaining to the FY21 PCRP Overarching Challenges. Support from this award is directed toward consortium infrastructure needs rather than direct support of the research itself. The principal goal of the Clinical Consortium Award is to combine the efforts of leading investigators to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease the impact of the disease. To facilitate global investigations, Principal Investigators (PIs) from both U.S. and international institutions are encouraged to apply. Submissions from institutions with enhanced access to patients from high-risk, underserved, and/or military populations (as described in the FY21 PCRP Overarching Challenges) are especially encouraged. The FY21 PCRP Clinical Consortium Award mechanism will be used to select and fund approximately 10 Clinical Research Sites and one Coordinating Center. NEW FOR FY21: In addition, the consortium will include two or more identified Affiliated Clinical Research Sites to be supported and managed by the Coordinating Center. Affiliated Clinical Research Sites should have enhanced access to patients from high-risk, underserved, and/or military populations. PIs will be required to indicate whether the institution is applying as either the Coordinating Center with a Clinical Research Site or a Clinical Research Site only. Institutions applying as the Coordinating Center, if not selected for funding, have the option to still be considered as a Clinical Research Site only. The Coordinating Center and Clinical Research Sites will be jointly responsible for proposing, selecting, and conducting phase 2 and phase 1/2 clinical trials focused on prostate cancer therapeutic interventions. Additional details regarding the structure of the consortium are described in detail below.

## Questions people ask

### Is W81XWH-21-PCRP-CCA still open?

No. It closed on September 23, 2021. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoD Prostate Cancer, Clinical Consortium Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoD Prostate Cancer, Clinical Consortium Award?

Closed September 23, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $30.7 million in total across about 11 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.